12/2/2021, 2:37 PM (Source: TeleTrader)
more TeleTrader news


Chart for: Valneva SE

EMA launches review of Valneva's COVID jab

The European Medicines Agency (EMA) announced on Thursday it started a rolling review of Valneva's COVID-19 vaccine.

The agency noted it launched the review based on non-clinical data that suggested the jab triggers the production of antibodies that target the coronavirus. "EMA will evaluate data as they become available to decide if the benefits outweigh the risks. The rolling review will continue until enough evidence is available for a formal marketing authorization application," the agency stated.

In November, the European Commission reached a deal with Valneva to secure 27 million doses of its vaccine in 2022 and another 33 million doses in 2023.

Baha Breaking News (BBN) / NP